Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma

Trial Profile

Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms NEXST
  • Sponsors Bayer
  • Most Recent Events

    • 11 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Mar 2014 Planned end date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top